Study | Treatment group | N | Age mean ± SD (years) | Age range (years) | Gender, n (%) | Time since first diagnosis of RVO mean ± SD (months) | Time since first diagnosis of RVO median [range] (months) | Baseline VA | |
---|---|---|---|---|---|---|---|---|---|
male | female | ETDRS letters analogue (mean ± SD)a | |||||||
Indication BRVO | |||||||||
OCEANb BRVO patients | Ranibizumab 0.5 mg | 204 | 71.2 ± 10.0 | 39.2-92.7 | 85 (41.7) | 119 (58.3) | 6.30 ± 16.35 c,d | 1.63 [0–127] c,d | 55.9 ± 20.9 |
BRAVO [50] | Sham injections (6 months) | 132 | 65.2 ± 12.7 | 26-89 | 74 (56.1) | 58 (43.9) | 3.7 ± 3.7 | 2 [0–16] | 54.7 ± 12.2 |
Ranibizumab 0.3 mg | 134 | 66.6 ± 11.2 | 43-90 | 67 (50.0) | 67 (50.0) | 3.6 ± 4.1 | 2 [0–35] | 56.0 ± 12.1 | |
Ranibizumab 0.5 mg | 131 | 67.5 ± 11.8 | 41-91 | 71 (54.2) | 60 (45.8) | 3.3 ± 3.1 | 2 [0–13] | 53.0 ± 12.5 | |
VIBRANT [51] | Laser | 90 | 63.9 ± 11.4 | n. a. | n. a. | 36 (40.0) | 1.4 ± 1.3 d | n. a. | 57.7 ± 11.3 |
Aflibercept 2 mg | 91 | 67.0 ± 10.4 | n. a. | n. a. | 47 (51.6) | 1.4 ± 1.4 d | n. a. | 58.6 ± 11.4 | |
Indication CRVO | |||||||||
OCEANb CRVO patients | Ranibizumab 0.5 mg | 121 | 70.3 ± 11.5 | 26.7-91.9 | 57 (47.1) | 64 (52.9) | 3.78 ± 6.49 c,d | 1.44 [0–38] c,d | 43.7 ± 25.0 |
CRUISE [52] | Sham injections | 130 | 65.4 ± 13.1 | 20-91 | 72 (55.4) | 58 (44.6) | 2.9 ± 2.9 | 2 [0–14] | 49.2 ± 14.7 |
Ranibizumab 0.3 mg | 132 | 69.7 ± 11.6 | 38-90 | 71 (53.8) | 61 (46.2) | 3.6 ± 3.2 | 2 [0–12] | 47.4 ± 14.8 | |
Ranibizumab 0.5 mg | 130 | 67.6 ± 12.4 | 40-91 | 80 (61.5) | 50 (38.5) | 3.3 ± 3.7 | 2 [0–27] | 48.1 ± 14.6 | |
COPERNICUS [53]e | Aflibercept 2 mg 2q4, then PRN | 114 | 65.5 ± 13.57 | n. a. | 69 (61) | 45 (39) | 2.73 ± 3.09 | n. a. | 50.7 ± 13.9 |
Sham injections 2q4, then Aflibercept 2 mg PRN | 73 | 67.5 ± 14.29 | n. a. | 38 (52) | 35 (48) | 1.88 ± 2.19 | n. a. | 48.9 ± 14.4 | |
GALILEO [54] | VEGF Trap-Eye (Aflibercept) 2q4 | 103 | 59.9 ± 12.4 | n. a. | 58 (56.3) | 45 (43.7) | 2.6 ± 2.9d | n. a. | 53.6 ± 15.8 |
Sham injections | 68 | 63.8 ± 13.3 | n. a. | 37 (54.4) | 31 (45.6) | 2.9 ± 2.6d | n. a. | 50.9 ± 15.4 |